VivoSeq
Other

Hypocalcemia

11

Pipeline Programs↗

3

Active Trials↗

9

Companies Involved↗

Hypocalcemia is an emerging landscape with 11 programs across 9 companies. The most active players are Calcilytix Therapeutics, Inc., a BridgeBio company, Takeda, Eli Lilly. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

80/100

Completion Rate

75/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Calcilytix Therapeutics, Inc., a BridgeBio company

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2A

Almaject

1 program

Phase 3AbbVie logo

AbbVie

1 program

ApprovedAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

13 of 14 classified programs — the dominant modality here.

7%ALL OTHERSPeptide17%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed6 · 46%
Recruiting3 · 23%
Unknown status2 · 15%
Terminated1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

13 trials

Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation
Recruiting·HHôpital NOVO·Phase 3·NCT04775381·200 enrolled
Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy
Recruiting·OOnze Lieve Vrouw Hospital·Phase 3·NCT05117853·300 enrolled
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Recruiting·CCalcilytix Therapeutics, Inc., a BridgeBio company·Phase 2/3·NCT07080385·28 enrolled
Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy
Completed·SSeoul National University Hospital·Phase 4·NCT05216419·108 enrolled
Routine Calcium for Preventing Hypocalcemia
Completed·EEwha Womans University Mokdong Hospital·N/A·NCT03484416·138 enrolled
Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial
Completed·CCentro de Excelencia en Enfermedades de Cabeza y Cuello·N/A·NCT05252884·258 enrolled
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
Completed·CCalcilytix Therapeutics, Inc., a BridgeBio company·Phase 2·NCT04581629·13 enrolled
Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).
Completed·SSaint Petersburg State University, Russia·Phase 3·NCT04750460·20 enrolled
A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Completed·Takeda logoTakeda·Phase 2·NCT02204579·7 enrolled
Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00623974·7 enrolled
Preoperative Vitamin D for Post-thyroidectomy Hypocalcemia
Withdrawn·UUniversity of Alberta·N/A·NCT01609439
Vit D Role in Post Thyroidectomy Hypocalcemia
Unknown status·—·Phase 1·NCT04094493·30 enrolled
The Incidence of Hypocalcemia in Pregnant Women at Siriraj Hospital
Unknown status·SSiriraj Hospital·N/A·NCT06160479·444 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)